DeCure for Bile Duct Adenoma

Bile duct adenoma is an extremely rare entity with only a few reported cases and limited knowledge about its natural progression. One case of biliary adenofibroma, a benign liver tumor of bile duct origin, showed transformation to intrahepatic cholangiocarcinoma. In a small series of three patients with tubular adenoma in the extrahepatic bile duct, all underwent resection of the common bile duct and Roux-en-Y cholangioenterostomy and recovered well; two of the three had moderate atypical hyperplasia on pathology. No drug treatment was used in any of these cases.

For distal common bile duct adenoma presenting with acute cholangitis, one patient was treated endoscopically with a combination of snare polypectomy and argon plasma coagulation. The authors note that appropriate therapeutic strategies for distal CBD adenomas have not been clearly defined. For adenocarcinoma of the extrahepatic bile ducts, surgical resection remains the gold standard, but management of loco-regional recurrences is not well defined; decisions are made based on clinical parameters from retrospective series such as tumor grade, surgical margins, or lymph node involvement.

No systemic drug therapy, targeted agent, or immunotherapy is reported for bile duct adenoma in these abstracts. One review of intrahepatic cholangiocarcinoma (a separate malignancy) states that surgical resection is the only effective treatment, that patients are often diagnosed at an advanced stage, and that mortality remains high; it discusses molecular targeted therapy as a topic of progress but provides no drug names or trial results for adenoma.

What is still missing: prospective studies that include molecular and genetic markers to improve patient selection and outcomes, a clearly defined therapeutic strategy for distal CBD adenomas, and any drug-repurposing trial or preclinical work specifically for bile duct adenoma. No funding source or trial design for such work is reported.